


January 9, 2025

Cain Brothers Industry Insights

Healthcare Market Report



Banker commentary:

Looking Back at 2024 and Forward to 2025

Banker Commentary

Contents

- Banker Commentary
- M&A Activity
- Private Placements
- Equity Capital Markets
- Public Equity Market Activity and Indices
- High Grade, High Yield & Leveraged Loans
- Public Finance Market
- Relevant News
- Recent Cain Brothers Transactions



Looking Back at 2024 and Forward to 2025

Banker Commentary by Wyatt Ritchie

The turn of the calendar provides opportunity to take inventory of the year that was, as well as look towards the year that lies ahead. For 2024, it was a year of mixed signals and desire for change. The S&P 500 was up 25% for the year (which followed a +26% increase in 2023); yet the 50+% increase in the market over the last two years did not assuage the U.S. electorate, and Trump 2.0 will be a major focus in 2025.

It's easy to look ahead, but given history is the best indicator of the future, a quick trip down 2024's memory lane makes sense. Below are the top 15 Fierce Healthcare stories of 2024, based on total page views during 2024:

- 1) *Change Healthcare begins breach notifications to firms with impacted members, patients*
- 2) *Humana exiting Medicare Advantage in 13 markets*
- 3) *UnitedHealth chief Andrew Witty was 2023's highest-paid payer CEO*
- 4) *Optum layoffs: Ohio facility closing, 129 employees impacted*
- 5) *Doctors, facing another pay cut in 2025, call for permanent Medicare payment reform*
- 6) *The 20 highest paid specialties in 2023 as doctors see 6% boost in pay*
- 7) *Optum WARN filing: 524 workers in California laid off*
- 8) *UPMC's layoffs were the start of a McKinsey-guided 'transformation'*
- 9) *Primary care player Forward shuts after raising \$400M*
- 10) *Walmart Health's shutdown underscores major challenges for retail health 'disruptors'*
- 11) *UnitedHealthcare CEO shooting suspect charged with first-degree murder as an act of terrorism*
- 12) *US hospitals prep for supply chain constraints in wake of Baxter International plant closure*
- 13) *Lurie Children's Hospital says nearly 800K patients' data compromised in cyberattack*
- 14) *CVS Health confirms layoffs in two states*
- 15) *Medicare Advantage star ratings 2025—Who are the winners and losers?*

In parsing the 2024 headlines, a few themes seem clear. One, change (disruption) in healthcare is hard. Two, technology provides both promise and risk. Three, we still have not figured out how to effectively deliver (or perhaps appropriately compensate) primary care. Four, the government, as reflected in Medicare Advantage changes or physician compensation, will likely continue to tighten the purse strings. And five, UnitedHealth continues to dominate the industry's headlines given its size and influence.

Despite change being hard, the election results suggest status quo is not desired. With the incoming administration promising change, it will be interesting to monitor the government's ability to implement change given healthcare's difficulties. Irrespective, the likely catalyst for change will be driven by economics rather than politics, and some of the Trump Administration's key influencers seem to believe government status quo is unsustainable – which will invariably have an impact on healthcare. Whether it's DOGE, RFK, Congress or other constituents, 2025 will likely begin to show the indicators of where the government would like to take the industry. Fortunately, the dollars devoted to healthcare are not the issue, it how they are allocated. Perhaps the DOGE will morph into DOHE – the Department of Healthcare Efficiency. The industry could use it.

continued...

For deal-making, the anticipated M&A boom in early 2024 did not meet expectations as the year unfolded, particularly for PE-backed platforms that were hoping to refresh ownership and capital structures. Some sectors saw an increase in M&A activity, while others were down. Large cap transaction values were up, as was transaction activity for small deals (i.e., tuck-ins and add-ons), but the middle-market was decidedly down. Anecdotes, conventional wisdom, and engaged pipelines suggest 2025 will be a busier year for M&A; and the pent-up supply of sponsor-owned businesses needing new partners will likely enter the market this year and next. Expect IPOs to also increase in 2025 as an investment exit given market dynamics and the need for alternatives to conventional M&A processes.

Many industry participants are making their way to San Francisco next week. The forecast is promising sunny weather, and, hopefully, the literal weather next week becomes the figurative environment for healthcare in 2025. That is this weatherman's prediction.

M&A Activity

Selected Recent Healthcare Transactions (\$MM)

Date	Target Name	Acquirer	EV	Enterprise Value /		Description
				LTM Rev.	LTM EBITDA	
1/8/2025	Central Maine Healthcare *	Prime Healthcare Foundation	NA	NA	NA	Not-for-profit, integrated healthcare system serving 400,000 people across central, western, and mid-coast Maine
1/2/2025	NeueHealth	New Enterprise Associates	\$1,300	1.3x	NM	Value-driven healthcare company delivering clinical care to over 500,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers
1/2/2025	Haven Behavioral Healthcare	Oceans Healthcare (Webster Equity Partners)	NA	NA	NA	Provider of specialty behavioral health services
12/30/2024	Prescott's (Atlantic Street Capital)	Morgan Stanley Capital Partners	NA	NA	NA	Specialty outsourced clinical engineering services provider
12/20/2024	Memora Health	Commure	NA	NA	NA	Digital care navigation platform
12/20/2024	Omega Healthcare Management Services	Ontario Teachers' Pension Plan and Goldman Sachs Alternatives	NA	NA	NA	Technology-enabled healthcare management solutions provider
12/18/2024	Apollo Care	Flexpoint Ford	NA	NA	NA	Provider of patient access and commercial solutions to the healthcare industry
12/18/2024	Boost Healthcare	Aspirion (Linden Capital Partners)	NA	NA	NA	Revenue cycle management provider
12/12/2024	Nationwide Medical	Heritage Group	NA	NA	NA	Provider of home medical equipment and clinical services for patients with chronic sleep and respiratory conditions
12/12/2024	Lake Norman Regional Medical Center (CHS)	Duke Health	\$280	NA	NA	123-bed North Carolina hospital
12/11/2024	Patterson Companies	Patient Square Capital	\$4,100	0.6x	12.3x	Dental and animal health distributor
12/11/2024	Theoria Management *	Amulet Capital Partners	NA	NA	NA	High-growth, tech-enabled, value-based primary care provider serving senior living communities
12/10/2024	Prescott's (Atlantic Street Capital)	Morgan Stanley Private Equity	NA	NA	NA	Healthcare focused specialty outsourced clinical engineering services provider
12/9/2024	Center for Social Dynamics	Goldman Sachs Alternatives and NMS Capital	NA	NA	NA	Provider of applied behavior analysis to children with Autism
12/4/2024	Cross Country Healthcare	Aya Healthcare	\$615	0.4x	19.8x	Tech-enabled workforce solutions across the continuum of care
12/4/2024	Focused Health	Bloom (Oak HC/FT)	NA	NA	NA	Health insurance distribution agency
12/4/2024	Zelis (minority stake)	Mubadala Investment Company, Norwest and HarbourVest	NA	NA	NA	Provider of payer focused healthcare technology solutions
12/3/2024	Nicklas Medical Staffing	Argosy Healthcare Partners	NA	NA	NA	Provider of staffing solutions nationwide to pathology and histology labs

Private Placement Activity

Selected Recent Healthcare Transactions (\$MM)

Date	Company	Investor(s)	Type	Amount	Description
12/30/2025	Royal Health	HealthQuest Capital	Minority	Undisclosed	Provider of advanced radiology software and workflow solutions
12/19/2024	Remodel Health	Oak HC/FT and Hercules Capital	Growth	\$100	Individual coverage health reimbursement arrangement provider
12/19/2024	U.S. Oral Surgery Management	Existing lenders	Credit Expansion	\$175	Physician practice management company focused exclusively on the oral and maxillofacial surgery specialty
12/17/2024	Pearl	American Dental Association	Strategic	Undisclosed	Dental AI solutions
12/11/2024	SpinSci	Aldrich Capital Partners	Majority	\$53	SaaS-based healthcare technology company
12/9/2024	Orthopedic Care Partners	Brookfield Asset Management	Recap	\$185	Orthopedic practice management platform
12/9/2024	Orthopedic Care Partners	TPG Twin Brook Capital Partners	Senior Credit Facility Refinancing	\$358	Orthopedic practice management platform
12/5/2024	Sollis Health	Foresite Capital (lead), Torch Capital, Montage Ventures, Freedom Partners, Read Capital, and One Eight Capital	Series B	\$33	Concierge medicine provider offering its members 24/7 access to ER-level diagnostics and capabilities
12/2/2024	Rock Dental	TPG Twin Brook Capital Partners (senior debt) and Audax Private Debt (mezzanine)	Debt	\$90	Dental service organization
11/26/2024	Sirona Medical	Avidity Partners (lead), 8VC, GreatPoint Ventures	Series C	\$42	Cloud-native radiology workflow software
11/21/2024	TailorMed	Windham Capital Partners (lead), Citi Impact Fund, Samsung Next, BrightEdge, Providence Ventures, OSF Healthcare, Inception Health, Ballard Ventures, UH Ventures, and UnityPoint Health Ventures	Equity and Debt	\$40	Enterprise solution manages the full lifecycle of patient support programs
11/20/2024	Zarminali Health	General Catalyst (lead)	Seed	\$40	Tech enabled outpatient pediatric care provider
11/19/2024	ÓURA	Dexcom	Series D	\$75	Smart ring that delivers personalized health data, insights, and daily guidance
11/18/2024	Seen Health	BVC (lead), Astrana Health, Basis Set Ventures, Primetime Partners and Virtue Ventures Management	Series A	\$22	Provider of medical care and social support for home and community-based services
11/13/2024	MB2 Dental	Warburg Pincus	Recap	\$525	Nationwide dental partnership organization
11/7/2024	Performance Home Medical	Grant Avenue Capital	Undisclosed	\$55	Medical equipment provider

Equity Capital Markets

Market Overview


- ECM activity wound down amidst the holiday break
- US ECM will finish 2024 having generated annual proceeds of roughly \$247 BN, up 73% from last year but still about 1/3 below the record volumes of 2021
 - IPO volume rose 130%+ YoY to nearly \$27 BN, but it remains 80% below 2021's nearly \$150 BN of proceeds (excluding SPAC IPOs)
 - Follow-on volume rose 80% to nearly \$146 BN
- The end of December brought few deals, but the lull could present an opportunity for companies wishing to go public in early 2025 to show their hand via IPO filings
 - Sponsor-backed medical supply firm Medline revealed it had filed confidentially for an IPO

ECM Activity (Last 4 Weeks & YoY)


	2024 - Last 4 Weeks			2023 - Last 4 Weeks		
	Vol (\$MM)	# Deals	% Share	Vol (\$MM)	# Deals	% Share
IPO	719	1	3%	0	0	0%
CONV	10,245	13	38%	3,064	6	31%
FO	16,349	35	60%	6,757	33	69%
Total	27,313	49	100%	9,821	39	100%

	2024 YTD			2023 YTD		
	Vol (\$MM)	# Deals	% Share	Vol (\$MM)	# Deals	% Share
IPO	26,494	52	11%	11,309	24	8%
CONV	75,673	98	31%	49,763	71	35%
FO	145,568	362	59%	81,172	308	57%
Total	247,734	512	100%	142,244	403	100%

U.S. ECM Offerings (LTM; IPOs, Follow-ons & Converts)



IPO & Follow-on 1-Week Performance (LTM)



Most Recent Healthcare Initial Public Offerings (\$MM)

Issuer Information				Deal Sizing			Pricing		Performance		
Pricing Date	Company	Sector	Ticker	Deal Value (\$MM)	Market Cap (\$MM)	Deal as % of Mkt. Cap	% Primary	Offer Price	Final Range	1-Day	1-Week
10/10/2024	Ceribell	Medical Products	CBLL	\$207.3	\$578.3	35.8%	100.0%	\$17.00	\$14.00 - \$16.00	47.1%	55.9%
7/24/2024	Concentra Group Holdings	Services	CON	\$546.4	\$2,992.6	18.3%	100.0%	\$23.50	\$23.00 - \$26.00	(4.3%)	(0.8%)
7/17/2024	Ardent Health Partners	Services	ARDT	\$220.8	\$2,255.4	9.8%	100.0%	\$16.00	\$20.00 - \$22.00	0.4%	4.7%
6/13/2024	Tempus AI	Healthcare Technology	TEM	\$410.7	\$6,098.8	6.7%	100.0%	\$37.00	\$35.00 - \$37.00	8.8%	(26.3%)
6/6/2024	Waystar Holding	Healthcare Technology	WAY	\$1,076.3	\$3,583.2	30.0%	100.0%	\$21.50	\$20.00 - \$23.00	(3.7%)	3.0%

Most Recent Healthcare Follow-on Offerings (\$MM)

Issuer Information				Deal Sizing			Pricing		Performance		
Pricing Date	Company	Sector	Deal Type	Ticker	Deal Value (\$MM)	Market Cap (\$MM)	Deal as % of Mkt. Cap	% Primary	Discount to File	1-Day	1-Week
12/12/2024	Anteris Technologies	Medical Products	Marketed	AVR	\$88.8	\$378.8	23.4%	100.0%	(11.5%)	(6.7%)	(3.7%)
11/19/2024	QuidelOrtho	Medical Products	Bought	QDEL	\$294.1	\$2,594.8	11.3%	0.0%	(7.7%)	5.3%	15.1%
11/7/2024	GE HealthCare Technologies	Medical Products	Bought	GEHC	\$1,173.1	\$40,355.6	2.9%	0.0%	0.0%	(2.7%)	(6.1%)
10/29/2024	PROCEPT BioRobotics	Medical Products	Marketed	PRCT	\$201.2	\$5,231.5	3.8%	100.0%	0.0%	2.2%	4.9%
10/2/2024	Pennant Group	Services	Marketed	PNTG	\$124.8	\$1,097.8	11.4%	100.0%	(13.2%)	9.1%	9.4%

Most Recent Healthcare Convertible Debt Offerings (\$MM)

Issuer Information				Deal Sizing			Pricing	
Pricing Date	Company	Sector	Ticker	Deal Value (\$MM)	Market Cap (\$MM)	Deal as % of Mkt. Cap	Coupon	Premium
12/16/2024	LeMaitre Vascular*	Medical Products	LMAT	\$172.5	\$2,070.8	8.3%	2.50%	30.00%
5/23/2024	HAEMONETICS	Medical Products	HAE	\$700.0	\$4,580.3	15.3%	2.50%	30.00%
3/6/2024	Tandem Diabetes Care	Medical Products	TNDM	\$316.3	\$1,778.9	17.8%	1.50%	27.50%
3/4/2024	iRhythm Technologies	Medical Products	IRTC	\$661.3	\$3,378.2	19.6%	1.50%	35.00%
12/6/2023	Merit Medical Systems	Medical Products	MMSI	\$747.5	\$3,784.4	19.8%	3.00%	32.50%

Sources: Bloomberg, Capital IQ, Dealogic, and Press Releases

Note: Transactions include IPOs, follow-ons (including bought deals) and convertible offerings of \$25mm or more priced on a U.S.-based exchange; Price performance includes both marketed and bought deal follow-ons; * denotes Cain Brothers / KBCM transaction; excludes fixed price IPOs

Transaction occurred the past week


Public Equity Market Activity & Indices

Equity Indices (as of January 3, 2025)

Index	Wk Open	Wk Close	Returns	
			52 Week	Weekly
DJIA	42,992	42,732	14.1%	(0.6%)
S&P 500	5,971	5,942	26.7%	(0.5%)
NASDAQ	19,722	19,622	35.2%	(0.5%)
Russell 2000	2,245	2,268	15.9%	1.1%
NYSE Healthcare	24,574	24,560	(0.7%)	(0.1%)

Cain Brothers Indicies	Returns	
	52 Week	Weekly
Acute Care	8.3%	(2.1%)
Alternate Site Services	9.6%	0.6%
Diagnostics	13.6%	(0.8%)
Distribution	9.6%	0.3%
Healthcare IT	12.7%	(0.6%)
Healthcare REITs	39.5%	0.5%
Managed Care	(13.0%)	0.7%
Medical Technology	9.3%	(0.3%)
Outsourced Services	(25.6%)	1.3%
Pharma Services	2.2%	(0.9%)
Pharmacy	(46.4%)	2.4%
Primary Care	(59.5%)	1.9%
Post-Acute Care Services	14.7%	0.1%
Post-Acute Care Facilities	10.2%	(0.2%)

Cain Brothers Healthcare Indices (1YR Performance)



High Grade, High Yield & Leveraged Loan Market

Market Summary

High Grade

- IG Bond primary market issuance saw 13 issuers tap the market to raise \$18.0 BN last week, clearing expectations of \$15 BN; December total issuance of \$41.7 BN has surpassed estimates of \$40 BN.


High Yield

- New supply of \$6.4 BN across six transactions cleared the market last week.


Term Loan B Market

- New issue CLO volume has remained strong in December, with more than \$80 BN more in issuance this year as opposed to last year at this point.

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$BN)



New-Issue Clearing Yields¹ (\$MM)

Double-B Issuers	2Q24	3Q24	30-Day Rolling Average	
			12/13/24	
Ba1	S+219 / 7.5%	S+192 / 7.0%	S+189	/ 6.4%
Ba2	S+236 / 7.5%	S+192 / 7.0%	S+192	/ 6.4%
Ba3	S+238 / 7.7%	S+268 / 7.9%	S+239	/ 6.9%
Single-B Issuers	2Q24	3Q24	30-Day Rolling Average	
			12/13/24	
B1	S+313 / 8.6%	S+333 / 8/6%	S+271	/ 7.2%
B2	S+373 / 9.1%	S+363 / 8.9%	S+335	/ 7.9%
B3	S+392 / 9.4%	S+394 / 9.3%	S+364	/ 8.2%

Most Recent Healthcare High-Grade Issuances (\$MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	IPT-Pricing
12/3/2024	CVS Health Corp *	Sub-Notes	\$2,250	Baa3/BB+/-	700.000%	3/10/2055	--	43 bps
12/3/2024	CVS Health Corp *	Sub-Notes	\$750	Baa3/BB+/-	675.000%	12/10/2054	--	55 bps
12/2/2024	Cencora Inc	Sr Notes	\$500	Baa2/BBB+/A-	462.500%	12/15/2027	+55	30 bps
12/2/2024	Cencora Inc	Sr Notes	\$600	Baa2/BBB+/A-	485.000%	12/15/2029	+77	28 bps
12/2/2024	Cencora Inc	Sr Notes	\$700	Baa2/BBB+/A-	515.000%	2/15/2035	+97	28 bps
11/13/2024	Cardinal Health Inc	Sr Notes	\$500	Baa2/BBB/BBB	4.700%	11/15/2026	+45	20 bps
11/13/2024	Cardinal Health Inc	Sr Notes	\$750	Baa2/BBB/BBB	5.000%	11/15/2029	+70	20 bps

Most Recent Healthcare High-Yield Issuances (\$MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	Price Talk
12/3/2024	US Acute Care (add-on) *	Sr. Sec. Notes	\$200	B3/B-NR	9.750%	5/15/2029	460 bps	102.50%-103.00%
11/18/2024	Select Medical	Sr. Notes	\$550	B1/B-NR	6.250%	12/1/2032	187 bps	6.25% area
11/13/2024	Molina Healthcare	Sr. Notes	\$750	Ba2/BB-NR	6.250%	1/15/2033	182 bps	6.375% area

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

Date	Issuer	Ownership	Corp. Ratings	Use of Proceeds	Size	Pricing	Yield
12/13/2024	Examworks Group Inc	CVC	B2 / B	Refinancing	\$2,458	SOFR+275, 0.50% @ 100	7.132%
12/13/2024	MDVIP Inc	Goldman Sachs Asset Management	B3 / B	Refinancing	\$736	SOFR+300, 0.50% @ 100	7.382%

Most Recent Healthcare Pro Rata Issuances (\$MM)


Date	Issuer	Ownership	Ratings	Use of Proceeds	Size	Pricing (in bps)	Financial Covenants
9/30/2024	Emergent BioSolutions	Public	B3 / B-	Refinancing	\$100mm 5-year ABL Revolver	Leverage-based Grid SOFR+175-225	Min Fixed Charge Coverage: 1.0x Min Liquidity

Public Finance Market


Market Overview

- The yield on the benchmark 10-year U.S. Treasury Note decreased 2 bps week-over-week, closing at 4.60% on Friday. 10-year MMD decreased 4 bps week over week
- Healthcare Public Issuance outpaced 2023. 2024 issuance increased 143% vs 2023.
- Muni bond funds saw \$387 MM of outflows while high yield funds gained \$20 MM for the week ended January 3rd.

MMD & UST Yield Curve




Weekly New Issue Volume (\$MM)



Benchmark Yields

Treasury Yields			MMD Yields			Ratio
Yr	Yield	Δ (W/W)	Yr	Yield	Δ (W/W)	MMD/UST
2	4.28%	- 3 bps	2	2.76%	- 6 bps	65%
10	4.60%	- 2 bps	10	3.04%	- 4 bps	66%
30	4.82%	0 bps	30	3.89%	- 3 bps	81%

Healthcare Public Issuance Overview



Recent Healthcare Public Issuance

Healthcare Public Issuance										
Borrower/Enhancement	Par (000s)	State	Issuer	Tax Status	LT Ratings (M/S/F)	Final Mat.	Call, Put or Reprice*	Final Mat. Cpn.	YTW	YTM
Recent Pricings, Week of 12/30										
No Recent Pricings										
Exp. Pricings, Week of 1/6										
Kahala Nui Project	131,745	HI	PFA	TE	NR / NR / A+	-	-	-	-	-

Relevant News

Eating Disorder Outlook 2025: M&A On The Rise, GLP-1s Impact Treatment¹

Behavioral Health Business | December 31, 2024

The eating disorder treatment sector has transformed dramatically in the past few years, with 2025 poised to bring further disruption through virtual care expansion, market consolidation and evolving patient needs. This evolution is occurring on the heels of a string of notable eating disorder treatment facility closures in 2023 and 2024. Despite the shuttering of multiple players in the field, 2025 will be a prime year for increased investment, de novo growth and mergers and acquisitions, according to top industry leaders. Providers looking to thrive must still hone their research, clinical and growth techniques. Focusing on cutting-edge treatments, coping with new challenges, including GLP-1 medications' impact on eating disorders, and advocating for reduced stigma will keep providers occupied in the new year.

Premiums Could Rise, Millions Could Lose Coverage If Enhanced ACA Subsidies Expire: CBO²

Healthcare Dive | December 10, 2024

During the COVID-19 pandemic, the Biden administration put in place enhanced tax credits for Americans who buy health insurance coverage via the ACA marketplaces. Beneficiaries with incomes between 100% and 400% of the federal poverty level received higher premium tax credits under the financial assistance. Those with incomes above 400% of the federal poverty level — who were previously completely ineligible — could also qualify. The subsidies were extended until the end of 2025.

HHS Releases Latest Round Of Prescriptions In Medicare Rebate Program Including Cancer Drugs³

Fierce Healthcare | December 20, 2024

The Centers for Medicare and Medicaid Services announced Friday that 64 Part B drugs will have a reduced price for Medicare patients at the pharmacy counter in the first quarter of 2025. CMS said patients may save between \$1 and \$10,818 per day on co-insurance costs for the Part B drugs included on the list. As part of the Inflation Reduction Act, drug manufacturers must give rebates to the federal government for single source drugs and biological products, including certain biosimilar biological products, whose price increased more than the rate of inflation. The list of discounted drugs changes each quarter.

1. <https://bhbusiness.com/2024/12/31/eating-disorder-outlook-2025-ma-on-the-rise-glp-1s-impact-treatment/>

2. <https://www.healthcarediver.com/news/aca-enhanced-subsidies-expire-millions-uninsured-premium-increase-congressional-budget-office/735012/>

3. <https://www.fiercehealthcare.com/payers/cms-releases-list-64-part-b-drugs-reduced-co-insurance-10k-q1>

Relevant News

The Radiologist Shortage, Explained¹

Becker's Hospital Review | December 31, 2024

The physician shortage is a pressing concern for healthcare, with radiology among the specialties facing some of the most significant challenges. The worldwide shortage of radiologists comes amid rising demand for their expertise, driven by an aging population and an unprecedented number of radiologists retiring after the stress of the pandemic. The American College of Radiology warns that the shortage will worsen as the number of imaging studies ordered continues to rise. The group forecasts that, by 2025, the number of annual imaging studies will surpass one billion, further straining an already burdened radiologist workforce. Much attention is being paid to this worrisome problem and the possible solutions, which range from the adoption of new artificial intelligence tools to federal legislation to increase funding for residency positions.

The "Amazon Effect" On Pharmacy Isn't About Medicine²

Axios | January 2, 2025

America's largest pharmacy chains are having a tough time competing with Amazon, and it isn't primarily because of medicine sales. The big picture: CVS and Walgreens have long boosted their margins by selling products that customers find on their way to pharmacies at the back of their stores, but that model is no longer working. Zoom in: Both incumbents have reported declining retail sales, with Walgreens citing a "challenging" retail environment that reads like code for locked-up items and "Amazon." Catch up quick: Walgreens in June announced plans to shutter a "significant" number of its 8,600 U.S. stores, and reportedly is in talks to be acquired by a private equity firm. Behind the scenes: While Amazon Pharmacy represents an existential threat to incumbents, it's not what's forcing retail stores into immediate crisis.

Meet The Healthcare Leaders Of The New GOP Congress³

Modern Healthcare | December 12, 2024

President-elect Donald Trump will be the new sheriff in town when he's sworn in Jan. 20, and he has a cadre of Republican deputies on Capitol Hill ready to lead legislative efforts on healthcare. The 119th Congress, which commences Friday, will be quite different from the previous Congress. In addition to occupying the White House, the GOP now controls the legislative branch after retaining the House and snatching the Senate majority from Democrats on Election Day. As happens every two years, 2025 brings a fresh start. All the legislation drafted and debated in 2023 and 2024 has ceased to exist. Lawmakers will have to start negotiations again on issues affecting Medicare, Medicaid, providers, health insurers, pharmacy benefit managers and more. The shift from a divided Congress to a legislature entirely in the GOP's hands is the biggest and most obvious change.

1. <https://www.beckershospitalreview.com/radiology/the-radiologist-shortage-explained.html>

2. <https://www.axios.com/2025/01/02/amazon-pharmacy-cvs-walgreens>

3. <https://www.modernhealthcare.com/politics-policy/house-senate-committee-chairs-help-finance-appropriations>

Recent Cain Brothers Transactions

<p>December 2024</p>  <p>has been acquired by</p>  <p>Sell-Side Advisor</p>	<p>Pending</p>  <p>has agreed to acquire</p>  <p>a subsidiary of</p>  <p>Buy-Side Advisor</p>	<p>November 2024</p>  <p>has been acquired by</p>  <p>Sell-Side Advisor</p>	<p>November 2024</p>  <p>a subsidiary of</p>  <p>has been acquired by</p>  <p>Sell-Side Advisor</p>
<p>October 2024</p>  <p>a portfolio company of</p>  <p>\$855,000,000 Senior Secured Credit Facilities</p> <p>Joint Lead Arranger & Joint Bookrunner</p>	<p>October 2024</p>  <p>a subsidiary of</p>  <p>has been acquired by</p>  <p>Buy-Side Advisor</p>	<p>October 2024</p>  <p>has acquired</p>  <p>Buy-Side Advisor</p>	<p>October 2024</p>  <p>a portfolio company of</p>  <p>\$635,000,000 Senior Secured Credit Facilities</p> <p>Left Lead Arranger, Joint Bookrunner & Administrative Agent</p>
<p>October 2024</p>  <p>has completed an affiliation agreement with</p>  <p>Buy-Side Advisor</p>	<p>September 2024</p>  <p>has been acquired by</p>  <p>Sell-Side Advisor</p>	<p>Pending</p>  <p>Indiana University Health</p> <p>has agreed to sell its health plan business to</p>  <p>Sell-Side Advisor</p>	<p>September 2024</p>  <p>has acquired</p>  <p>Buy-Side Advisor</p>
<p>September 2024</p>  <p>Senior Secured Credit Facilities</p> <p>provided by</p>  	<p>August 2024</p>  <p>\$33,785,000 Adjustable-Rate Hospital Revenue Refunding Bonds (Tax Exempt)</p> <p>Sole Manager</p>	<p>Pending</p>  <p>a subsidiary of</p>  <p>has agreed to be acquired by</p>  <p>Financial Advisor</p>	<p>June 2024</p>  <p>has been acquired by</p>  <p>Sell-Side Advisor</p>

Senior Investment Banking Team

Leadership



Wyatt Ritchie
 (415) 450-7856
 writchie@cainbrothers.com
Group Head

Information Technology



Jill Frew
 (212) 981-6916
 jfrew@cainbrothers.com
Payer Software / Digital Health / B2C



Thad Davis
 (917) 368-2366
 tdavis@cainbrothers.com
HealthTech / Digital Health / Services

Life Sciences / MedTech



Carl Hardie
 (718) 887-6221
 chardie@cainbrothers.com
Outsourced Medical Manufacturing & Service Providers



Roman Rezanowicz
 (212) 981-6928
 rrezanowicz@cainbrothers.com
Pharma Services & Technology



Lee Sophocleous
 (212) 476-7438
 lsophocleous@cainbrothers.com
Pharma Services / CDMOs



Sean Trail
 (312) 360-3883
 strail@cainbrothers.com
MedTech Products & Services / Tools & Diagnostics

Payers



Mike Elizondo
 (415) 962-2951
 melizondo@cainbrothers.com
Managed Care / Care Coordination



Stacy Guffanti
 (212) 981-6925
 sguffanti@cainbrothers.com
Managed & Value-Based Care / Women's Health



Court Houseworth
 (415) 962-2956
 chouseworth@cainbrothers.com
Managed Care / Specialty Managed Care

Providers




Patrick Allen
 (630) 542-8734
 pallen@cainbrothers.com
Multi-Site / Physician Groups / Practice Management



David Cohen
 (212) 297-2723
 dcohen@cainbrothers.com
Hospitals & Health Systems



Dan Gold
 (847) 219-6670
 dgold@cainbrothers.com
Primary & Value-based Care



Andy Goldberg
 (212) 981-6898
 agoldberg@cainbrothers.com
Distribution / Logistics / Human Capital Outsourcing



Erika Haanpaa
 (212) 297-2754
 ehaanpaa@cainbrothers.com
Behavioral Health



Andy Labovitz
 (212) 981-6940
 alabovitz@cainbrothers.com
Hospitals & Health Systems



Matthew Margulies
 (212) 981-6938
 mmargulies@cainbrothers.com
Home Health & Hospice / Pharmacy / Distribution




Jim Moloney
 (415) 962-2961
 jmoloney@cainbrothers.com
Hospitals & Health Systems / Physician Groups



David Morlock
 (312) 604-0575
 dmorlock@cainbrothers.com
Hospitals & Health Systems / Physician Groups



Todd Rudsenske
 (617) 385-6265
 trudsenske@cainbrothers.com
Behavioral Health / Multi-Site



Jonah Schutzman
 (212) 476-7445
 jschutzman@cainbrothers.com
Physician Practice Management



Jenny Watson
 (216) 689-7701
 jwatson@cainbrothers.com
Dental / Health & Beauty

Healthcare Product Partners



Steve Alcauskas
 (503) 821-3999
 steven.alcauskas@key.com
Lending / Banking Products



Carl McCarden
 (646) 279-7621
 cmccarden@key.com
Sponsor Coverage



Ryan Stilphen
 (440) 915-6687
 ryan.stilphen@key.com
Leveraged Finance



Mark Barath
 (216) 689-4747
 mbarath@key.com
Equity Capital Markets

Senior Public Finance Team



Zach Kau
(415) 486-3422
zach.kau@key.com




Kyle Hemminger
(614) 460-3448
khemminger@cainbrothers.com



Dominic Porretta
(212) 981-6955
dporretta@cainbrothers.com



Bart Plank
(212) 981-6915
bplank@cainbrothers.com



Kathy Kirchhoff
(562) 264-0300
kkirchhoff@cainbrothers.com



Taaha Shaikh
(212) 981-6903
tshaikh@cainbrothers.com



James Conahan
(212) 981-6893
jconahan@cainbrothers.com




Joe Mulligan
(314) 800-0441
jmulligan@cainbrothers.com



Joanna Stephenson
(646) 205-0276
jstephenson@cainbrothers.com



Maura Davalos
(716) 819-5354
mdavalos@cainbrothers.com



Joe Pollock
(415) 962-2957
jpollock@cainbrothers.com



Chris Whitley
(805) 302-3293
cwhitley@cainbrothers.com

Industry Insights is compiled weekly by Cain Brothers, 1301 Avenue of the Americas, 37th Floor, New York, NY 10019 Ph: (212) 869-5600. To receive our Industry Insights email, please register on www.cainbrothers.com. For questions regarding Industry Insights please email rgruber@cainbrothers.com

The information contained in this report was obtained from various sources, including third parties, that we believe to be reliable, but neither we nor such third parties guarantee its accuracy or completeness. Additional information is available upon request. The information and opinions contained in this report speak only as of the date of this report and are subject to change without notice. This report has been prepared and circulated for general information only and presents the authors' views of general market and economic conditions and specific industries and/or sectors. This report is not intended to and does not provide a recommendation with respect to any security. Cain Brothers, a division of KeyBanc Capital Markets ("Cain Brothers"), as well as any third-party information providers, expressly disclaim any and all liability in connection with any use of this report or the information contained therein. Any discussion of particular topics is not meant to be comprehensive and may be subject to change. This report does not take into account the financial position or particular needs or investment objectives of any individual or entity. The investment strategies, if any, discussed in this report may not be suitable for all investors. This report does not constitute an offer, or a solicitation of an offer to buy or sell any securities or other financial instruments, including any securities mentioned in this report. Nothing in this report constitutes or should be construed to be accounting, tax, investment or legal advice. Neither this report, nor any portions thereof, may be reproduced or redistributed by any person for any purpose without the written consent of Cain Brothers and, if applicable, the written consent of any third-party information provider.

"Cain Brothers, a division of KeyBanc Capital Markets" is a trade name of KeyBanc Capital Markets Inc. Member FINRA/SIPC.

KeyBanc Capital Markets Inc. and KeyBank National Association are separate but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives. Banking products and services are offered by KeyBank National Association. Credit products are subject to credit approval. Copyright © 2025 KeyCorp.